Purine synthesis and metabolism enzymes

Purine synthesis and metabolism enzymes represent a critical group of proteins responsible for the de novo production and salvage of purine nucleotides (StatPearls: Purine Metabolism, 2023). These nucleotides, including adenine and guanine, are essential building blocks for DNA and RNA synthesis and serve as primary energy carriers like ATP and GTP (UniProt: IMPDH1, 2024). The metabolic network is divided into the de novo pathway, which constructs the purine ring from basic precursors, and the salvage pathway, which recycles bases from degraded nucleic acids (NCBI: Purine Metabolism, 2022). Because rapidly proliferating cells, such as malignant cells and activated T-cells, rely heavily on these pathways, they are prime targets for therapeutic intervention (PubMed: Nucleotide Metabolism in Cancer, 2021). Pharmacological agents like mycophenolate mofetil and methotrexate inhibit key enzymes such as inosine monophosphate dehydrogenase and dihydrofolate reductase, respectively (PubChem: Mycophenolate, 2024). This inhibition leads to the depletion of intracellular nucleotide pools, effectively halting DNA replication and inducing cell cycle arrest or apoptosis (NIH: Thiopurines, 2023). Consequently, these targets are vital in treating various conditions, including leukemia, autoimmune disorders, and gout.

Other names

Purine metabolic pathwayPurine nucleotide biosynthesisPurine salvage pathwayPurine metabolismPurine biosynthesis

Drugs targeting these enzymes typically act as competitive inhibitors or antimetabolites that disrupt the production of purine nucleotides. By inhibiting key enzymes such as inosine monophosphate dehydrogenase (IMPDH) or dihydrofolate reductase (DHFR), these agents deplete the intracellular pools of ATP, GTP, dATP, and dGTP, which are essential for DNA polymerases and RNA polymerases to function, ultimately leading to the inhibition of cell proliferation and induction of apoptosis (StatPearls: Purine Metabolism, 2023; PubChem: Methotrexate, 2024).